Regulatory approval

Published by the Health Service Executive. Withdrawn

The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with FOLFIRI (14 days) for reimbursement as a treatment option for the treatment of adult patients with RAS wild type metastatic colorectal cancer. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.

This is written in the approval document as:

Treatment of patients with RAS wild type metastatic colorectal cancer.

Reimbursement

N/A

Citation

Cetuximab (7 days) and FOLFIRI (14 days) Therapy, 2026, version number 7, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6773/328_v6b_Cetuximab_7_days_FOLFIRI_14_Days.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-06-03	Health Service Executive	Indication approved for reimbursement.